Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Epigenetics: official journal of the DNA Methylation Society (Impact Factor: 5.11). 02/2012; 7(2):201-7. DOI: 10.4161/epi.7.2.19015
Source: PubMed

ABSTRACT TET2 enzymatically converts 5-methyl-cytosine to 5-hydroxymethyl-cytosine, possibly leading to loss of DNA methylation. TET2 mutations are common in myeloid leukemia and were proposed to contribute to leukemogenesis through DNA methylation. To expand on this concept, we studied chronic myelomonocytic leukemia (CMML) samples. TET2 missense or nonsense mutations were detected in 53% (16/30) of patients. In contrast, only 1/30 patient had a mutation in IDH1 or IDH2, and none of them had a mutation in DNMT3A in the sites most frequently mutated in leukemia. Using bisulfite pyrosequencing, global methylation measured by the LINE-1 assay and DNA methylation levels of 10 promoter CpG islands frequently abnormal in myeloid leukemia were not different between TET2 mutants and wild-type CMML cases. This was also true for 9 out of 11 gene promoters reported by others as differentially methylated by TET2 mutations. We found that two non-CpG island promoters, AIM2 and SP140, were hypermethylated in patients with mutant TET2. These were the only two gene promoters (out of 14,475 genes) previously found to be hypermethylated in TET2 mutant cases. However, total 5-methyl-cytosine levels in TET2 mutant cases were significantly higher than TET2 wild-type cases (median = 14.0% and 9.8%, respectively) (p = 0.016). Thus, TET2 mutations affect global methylation in CMML but most of the changes are likely to be outside gene promoters.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Peripheral T cell lymphomas (PTCL) are classified as mature T cell neoplasms. However, several new findings support the notion that premalignant cells arise in the immature stage of hematopoietic differentiation, and subsequently evolve into full-blown T-lineage tumor cells. Acquisition of (Ten-Eleven Translocation 2) TET2 mutations may be an important event for the establishment of premalignant cells. In PTCL harboring features of follicular helper T cells, tumor-specific G17V RHOA mutations co-occur with premalignant TET2 mutations. The G17V (ras homolog family member A) RHOA mutations may play important roles in clonal evolution of premalignant cells into tumor cells. Indeed, multistep tumorigenesis is thought to be essential for pathogenesis of PTCL.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In the last five years, IDH1 mutations in human malignancies have significantly shaped the diagnosis and management of cancer patients. Ongoing intense research efforts continue to alter our un-derstanding of the role of the IDH1 mutation in tumor formation. Currently, evidence suggests the IDH1 mutation to be an early event in tumorigenesis with multiple downstream oncogenic con-sequences including maintenance of a hypermethylator phenotype, alterations in HIF signalling, and disruption of collagen maturation contributing to a cancer-promoting extracellular matrix. The most recent reports elucidating these mechanisms is described in this review with an emphasis on the pathogenesis of the IDH1 mutation in glioma. Conflicting findings from various studies are discussed, in order to highlight areas warranting further research. Finally, the latest progress in developing novel therapies against the IDH1 mutation is presented, including recent findings from ongoing phase 1 clinical trials and the exciting prospect of vaccine immunotherapy targeting the IDH1 mutant protein.
    International journal of medical sciences 01/2015; 12301(123301):201-213. DOI:10.7150/ijms.11047 · 1.55 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Only a minority of myelodysplastic syndrome (MDS) patients respond to hypomethylating agents, but strong predictors of response are not known. We sequenced 40 recurrently mutated myeloid malignancies genes in tumor DNA from 213 MDS patients collected prior to treatment with azacitidine or decitabine. Mutations were examined for association with response and overall survival. The overall response rate of 47% was not different between agents. Clonal TET2 mutations predicted response (odds ratio [OR] 1.99, p = 0.036) when subclones unlikely to be detected by Sanger sequencing (allele fraction <10%) were treated as wildtype. Response rates were highest in the subset of TET2 mutant patients without clonal ASXL1 mutations (OR 3.65, p = 0.009). Mutations of TP53 (hazard ratio [HR] 2.01, p = 0.002) and PTPN11 (HR 3.26, p = 0.006) were associated with shorter overall survival but not drug response. Murine competitive bone marrow transplantation followed by treatment with azacitidine demonstrated that Tet2-null cells have an engraftment advantage over Tet2-WT cells. Azacitidine significantly decreased this advantage for Tet2-null cells (p=0.002) but not Tet2-WT cells (p=0.212). Overall, Tet2 loss appears to sensitize cells to treatment with azacitidine in vivo and TET2 mutations can identify patients more likely to respond to hypomethylating agents.
    Blood 09/2014; 124(17). DOI:10.1182/blood-2014-06-582809 · 9.78 Impact Factor

Full-text (2 Sources)

Available from
May 22, 2014